Ethical considerations in biomedical HIV prevention trials
Well into the third decade of the HIV epidemic, there remains no effective HIV preventive vaccine, microbicide, product or drug to reduce the risk of HIV acquisition. As the numbers of those infected by HIV and dying from AIDS continue to increase, the need for such biomedical HIV preventive interventions becomes ever more urgent. Several such products are at various stages of development, including some currently in phase III efficacy trials. The successful development of effective HIV preventive interventions requires that many different candidates be studied simultaneously in different populations around the world.
Related feature storiesFirst Lady of Kenya runs half marathon to end new HIV infections among children and improve the lives of mothers
11 March 2014New advances in HIV research and development
10 March 2014Better development outcomes through participation: The role of women, the young people and civil society in the post-2015 debate
10 March 2014